Cannabis Studied as Treatment for Alzheimer’s Disease
The estimated number of patients suffering from Alzheimer’s disease is around 35 million people worldwide, and it may triple by 2050. Realm of Caring (RoC), a US based non-profit organization, believes that the growing access to CBD and other substances found in cannabis can help control the symptoms of Alzheimer and should be studied as a way to prevent, slow down, or even reverse its progression.
Cannabinoids Reduce Aggression and Agitation in Alzheimer Patients
Alzheimer’s disease—which increasingly affects the world’s aging population—is a neurodegenerative disorder that causes a decline in cognitive abilities and a change in personality. It is most commonly observed in senior citizens, but can sometimes lead to disability in middle-aged patients.
Various constituents of the cannabis plant have been studied as a way to control symptoms of the disease. RoC—which operates from Colorado Springs, Colorado, USA—reports that at least 6 studies have demonstrated that cannabinoids successfully reduce the severity of aggression and agitation associated with Alzheimer.
As many as 55 percent of Alzheimer patients display symptoms of agitation which include restlessness, pacing, screaming, and such signs of anxiety as hand wringing. Many patients also behave aggressively: they shout at their caregivers and insult them, through objects, and sometimes hit and bite. A treatment that reduces such behavior could be of great value.
Non-cannabinoid Treatments Have Limited Efficacy and Severe Side Effects
In the initial stages of Alzheimer’s disease, patients often receive such non-pharmacological treatments as person-centred care, structured social interaction, and even music therapy. These, however, can’t stop the progress of the disorder, and the worsening conditions require the administration of drugs.
Some medical professionals argue that the adverse effects from these drugs offset their potential advantages. Moreover, prescribed medications have so far failed to fully treat Alzheimer’s disease. A new approach to curing it is necessary.
Nicolas Schlienz, PhD, research director at RoC, advocates the use of cannabinoids not only for treating the symptoms of the disease but also for trying them as a means to prevent, slow down, or even reverse Alzheimer.
He stresses that ECS, the body’s own endocannabinoid system, with its receptors responding to CBD, THC, and other substances produced by cannabis, is a promising target for cannabinoid-based medications.
ECS plays an important role in producing neuroprotective and anti-inflammatory effects. It can also be used to reduce oxidative stress. All this warrants further research into the plant’s ability to provide symptom relief and potentially slow the progression of Alzheimer.
MEDICAL DISCLAIMER
This content is for educational purposes only. The information provided is derived from research gathered from external sources.
